Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,356JPY
2:00am EDT
Change (% chg)

¥2 (+0.06%)
Prev Close
¥2,354
Open
¥2,350
Day's High
¥2,362
Day's Low
¥2,344
Volume
1,569,700
Avg. Vol
1,909,773
52-wk High
¥2,670
52-wk Low
¥2,192

Select another date:

Tue, Aug 1 2017

BRIEF-Daiichi Sankyo and unit says settlement agreement on u.s. products liability litigation

* Says it and U.S.-based unit Daiichi Sankyo, Inc. have agreed to enter into a program to settle, on behalf of all defendants, pending product liability litigation against various Daiichi Sankyo and Forest entities

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar

NEW YORK Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness.

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar

NEW YORK Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness.

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar

NEW YORK, Aug 1 Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness.

BRIEF-Daiichi Sankyo announces settlement on U.S. products liability litigation

* Announces settlement agreement on U.S. Products liability litigation​

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

BRIEF-Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

* Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

BRIEF-Daiichi Sankyo to invest 22 bln yen in U.S. for Luitpold Pharmaceuticals - Nikkei

* Daiichi Sankyo to invest 22 billion yen in U.S. for Luitpold Pharmaceuticals; targets about 70 pct rise in Luitpold's sales to 150 billion yen in fiscal 2020 versus 2015 - Nikkei Source (http://s.nikkei.com/2qhFwVe) Further company coverage:

BRIEF-Daiichi Sankyo makes 15 bln yen investment

* Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline Source text for Eikon: Further company coverage:

Select another date: